background: Polycystic ovary syndrome (PCOS) is a heterogeneous disorder. However, PCOS has a strong resemblance to the metabolic syndrome, including preponderance of visceral fat deposition. The aim of this study is to compare fat distribution between lean women with PCOS and controls matched for body composition but with regular menstrual cycles and proven fertility.
Introduction
Polycystic ovary syndrome (PCOS) includes a series of heterogeneous clinical entities characterized by reproductive, hyperandrogenic and metabolic features. Obesity and fat distribution are supposed to play an important role in the aetiology of PCOS (Balen et al., 1995; Legro, 2000; Barber et al., 2006) . In an observational study in 2001 among 346 Dutch PCOS women, 56.1% had a BMI of ,25 kg/m 2 (defined as lean), 11.3% were between 25
and 27 kg/m 2 (overweight) and 32.7% were ≥27 kg/m 2 (obese) (Elting et al., 2001) .
Magnetic resonance imaging (MRI) is a highly accurate way to measure fat content at different body sites. By using MRI, it has been previously demonstrated that PCOS is not as closely linked to visceral adiposity as was hypothesized. In a recent study, comparing mildly obese women with PCOS against controls, visceral fat was preponderant among PCOS cases (whole group analysis). However, there was no difference in visceral fat content between groups after subgroup analysis (matched for BMI/fat mass ratio; Barber et al., 2008) . Since all PCOS studies have included subjects who are overweight or obese it is of interest to study this issue in lean women with PCOS (BMI of 19-25 kg/m 2 ) excluding bias caused by external obesity-related cues, such as food, overconsumption, sedentary lifestyle or drugs associated with weight gain. These external factors might change glucose metabolism that is considered to be critical in PCOS (Robinson et al., 1993; Dunaif, 1997; Franks et al., 2000; Morin-Papunen et al., 2000) .
In the current MRI study, we have compared lean PCOS cases with confirmed fertile controls (women with regular cycles who have had successful pregnancies). The primary focus was to study body fat distribution in these women and secondly to include MRI-derived volume calculations of the ovaries as additional information.
Materials and Methods

Patients
Ten lean (BMI 19 -25 kg/m 2 ) women, with PCOS according to ESHRE/ ASRM criteria, who were consecutively visiting the fertility clinic of Twente Group of Hospitals, Hengelo, The Netherlands, were recruited for participation in the current study. Twelve BMI-matched controls were recruited from the outpatient clinic for gynaecology and obstetrics. All participants were Dutch Caucasians. Individuals with known drug abuse, pregnant women or patients with general or endocrine disorders were excluded from participation. Of 12 selected controls, two subjects were excluded from the study as they failed to show up for MRI analysis despite informed consent. None of the controls met any of the diagnostic ESHRE/ASRM criteria for PCOS and all had previously completed at least one successful pregnancy. Control subjects did not use hormonalcontaining contraceptives and ovulatory menstrual cycles were confirmed by mid-luteal progesterone concentrations .16 nmol/l.
Inclusion of the numbers of cases was based on the original concept that visceral fat is preponderant in PCOS. Therefore, this study was powered on the findings of about 1 SD (standard deviation) difference in Mid-L4 visceral fat content (whole group analysis), as previously reported (Barber et al., 2008) . We assumed that the visceral abdominal content in women with PCOS is on average 1.25 SD different from controls, allowing the study of two groups (n ¼ 10 per group), ensuring 80% power with a significance level of 5%.
The diagnosis of PCOS was made using the Rotterdam ESHRE/ASRM diagnostic criteria (Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group, 2004a,b) . All included women had oligo-ovulation and/or anovulation (intermenstrual interval .42 days) and also typical polycystic ovaries shown on ultrasound; none of them had clinical and/or biochemical signs of hyperandrogenism. None of the subjects had ever received hormonal therapy for ovulation induction. Other endocrine or neoplastic causes of hyper-androgenaemia (including congenital adrenal hyperplasia, androgen-secreting tumours and Cushing's syndrome) were excluded on the basis of 8 a.m. fasting serum 17-hydroxyprogesterone (17-OH-Prog) ,3 mmol/l, serum cortisol ,0.54 nmol/l, dehydroepiandrosterone sulphate (DHEA-S) ,12.0 mmol/l, androstenedione (Ddione) ,14.4 nmol/l and absence of an ovarian tumour on intra-vaginal ultrasound. Fasting laboratory analyses and MRI assessments were performed on the same day during the follicular phase of the cycle in controls or after progesterone-induced withdrawal bleeding in all PCOS cases.
All clinical investigations were conducted in accordance with the guidelines in the Declaration of Helsinki, and the study was approved by the medical ethical review committee of the hospital. All subjects provided written informed consent.
Anthropometric and biochemical evaluation
Waist circumference (cm) was measured at the midpoint between the iliac crest and the lowest rib margin, just above the umbilicus at the end of normal expiration. Hip circumference (cm) was measured at the widest part of the buttocks. Bioelectrical impedance analysis (BIA) was performed using Quadscan equipment (version 4.04, Bodystat Ltd, Isle of Man, UK), measuring fat mass and lean body mass. Fasting venous blood samples were drawn from all participants on the study day (on cycle Days 3 -7) after spontaneous menses in controls or after progesterone-induced menses in PCOS. Samples were collected in serum separator tubes, allowed to clot for at least 30 min, centrifuged for 15 min at 2000g at room temperature and aliquoted into polypropylene tubes. All biochemical parameters were immediately assayed by using commercial kits. Serum was assayed for fasting glucose with an automated analyser (COBAS 6000, Roche Diagnostics, Almere, NL). Fasting insulin, C-peptide, estradiol (E2), 17-OH-Prog, DHEA-S, sex hormone-binding globulin (SHBG), FSH and LH were measured using chemiluminescence sandwich immunoassays (Siemens Healthcare Diagnostics, Breda, NL) and total testosterone (T) was measured with a direct (competitive) chemiluminescent assay (Siemens Healthcare Diagnostics, Breda, NL) on a fully automated analyser (IMMULITE w 2000, Siemens Healthcare Diagnostics, Breda, NL). Androstenedione assays were performed by Radioimmunoassay (RIA) after extraction and paper chromatography (Otten et al., 1983) .
Free androgen index (FAI) was calculated as total 2 T/SHBG multiplied by 100. Biochemical hyperandrogenism was defined as a T . 3.5 nmol/l and/or FAI . 8.5 as provided by the manufacturer. A model-derived estimate of insulin resistance was applied to calculate the homeostasis model assessment (HOMA) using a calculator (http://www.dtu.ox.ac.uk/ homacalculator/index.php).
Magnetic resonance imaging
MRI scans were performed on the day of blood sampling. All participants were examined on a Magnetom Harmony 1.0 T MRI system (Siemens Medical Solutions USA), using the integrated Body Coil for fat measurements and CP Body Array for ovarian volume measurements. The measurements were performed on the Leonardo Stand Alone Viewing console (Siemens Medical Solutions USA). The diagnostic console has a cursor area measurement facility for all dimensional measurements.
Assessment of body fat distribution in each subject was based on measurements of cross-sectional areas of fat depots, made from axial T1-weighted Turbo Spin-Echo images taken at the following anatomically predefined levels: the mid-lumbar L4 vertebral body (Mid-L4) for measurements of visceral and subcutaneous abdominal fat depots, the upper abdominal region from diaphragm to L4 and the lower abdominal region from L4 to the symphysis. In detail, multiple axial cross-sections were taken throughout the abdomen from the diaphragm to the pelvis and mean averages from all slices (10 mm each) in each women with PCOS were compared with the mean in the controls. In addition, measurements were performed at the greater trochanters to establish the gluteal subcutaneous fat depots and from diaphragm to symphysis to establish the whole abdomen fat depots. Slice thickness for abdominal fat measurements was 10 mm. One cross-sectional slice was taken at Mid-L4 (10 slices per group). The whole abdomen from diaphragm to symphysis included slices in PCOS and 155 slices in controls.
To determine ovarian volumes, T2-weighted axial and T2-trufi axial breath-hold sequences were used providing a two-dimensional measure. The third diameter was calculated by adding the total number of axial slices of 6 mm per ovary. Ovarian volumes were calculated as 2/3p × ovarian length × width × height.
Data for fat depot measurements disclosed a reproducibility of CV% (intra-observer): 2.5 + 1.4 (SD) and CV% (inter-observer): 2.6 + 1.5 (SD). For ovarian volumes, it was CV% (intra-observer): 3.3 + 2.0 (SD) and CV% (inter-observer): 6.3 + 7.9 (SD).
Statistical analyses
Statistical analyses were performed using Statgraphics Centurion XV software (Version 15.2.00 for MS Windows; Statpoint, Inc., VA, USA) and using Analyse-It (Version 2.21 for MS Excel; Analyse-It Software, Leeds, UK). Analyses included unpaired-sample t-tests for comparisons of demographic, laboratory and MRI data obtained from women with PCOS and controls. Shapiro-Wilks W-tests were used to check whether nominal parameters were normally distributed prior to analysis, and in case of skewness, Wilcoxon Rank tests were performed. P-values of ,0.05 were considered significant.
Results
Women with PCOS were on average 5.5 years younger than controls (PCOS: 28.2 + 2.6 years versus controls: 33.7 + 2.3 years, P , 0.0001). However, anthropometrics and BIA parameters (fat mass and lean body mass) were similar between the groups (Table I) .
PCOS cases had significant lower mean FSH and E2 levels and the calculated FAI was higher in the PCOS group. All other laboratory results were similar between groups, including fasting glucose, insulin, C-peptide and HOMA-insulin resistance (IR) ( Table II) .
MRI-determined assessments of the right and left ovarian volumes disclosed larger volumes in PCOS: 44.4% larger at the right side and 33.1% larger at the left side. None of the PCOS cases had ovarian volumes ,2.3 cm 3 or .6.8 cm 3 . Ovarian volumes below 2.3 cm 3 were found in 9 out of 10 control cases. Out of 10 control cases, 2 had bilateral ovarian volumes ,2.3 cm 3 (Table III) .
Visceral fat volumes calculated from single cross-sectional axial slices at Mid-L4 levels were similar between groups. However, comparing multiple cross-sections of the whole abdomen showed less visceral fat in PCOS cases, regardless of the region of interest: upper abdominal region: 52% less, lower abdominal region: 48% less and whole abdomen: 49% less. In PCOS, visceral fat measurements had a range of 274-854 cm 2 and in controls, the range was 644-1259 cm 2 . None of the PCOS cases had visceral contents .780 cm 2 , while eight control cases had visceral contents .780 cm 2 . Between groups, there were no differences between peripheral fat measurements at any abdominal site or greater trochanters (Table IV) . For both groups, there were no significant correlations between any of the laboratory parameters and right-or left-sided ovarian volumes. There were also no significant correlations between fat measurements at any site and right-or left-sided ovarian volumes.
Discussion
In the current study, we compared lean PCOS cases with matched controls with the main focus on differences in fat distribution. PCOS was strictly defined according to ESHRE/ASRM diagnostic criteria, and all women had typical polycystic ovaries upon intravaginal ultrasound. Control cases were fertile having achieved at least one successful pregnancy and did not take any hormone-containing contraceptive.
In contrast to expectation, the current results demonstrated that the content of visceral deposited fat was lower in PCOS cases. Since other anthropometric data except age were balanced, this finding points to higher lean body mass and lower fat mass in the PCOS cases. In addition, this discrepancy in body composition was not accompanied by differences in fasting glucose, insulin, C-peptide levels or HOMA calculations between groups. The current study is the third MRI study reporting the absence of preferential visceral fat accumulation in PCOS cases. Notably, the first MRI study included women with PCOS who were slightly obese (mean BMI: 28 kg/m 2 ) against controls (Barber et al., 2008) . and reported that the factor 'being obese' and not the factor 'being a PCOS patient' is predictive for insulin resistance. However, opposite results, i.e. significantly higher insulin resistance in PCOS were shown in a study (Dunaif et al., 1989) comparing younger women with PCOS and controls (mean age: 21.3 + 3.7 and 21.2 + 3.4 years, respectively) with normal body weights (BMI: 21.9 + 2.6 and 20.6 + 1.1 kg/m 2 , respectively). Pioneer clamp studies on insulin sensitivity in lean women with PCOS compared with perfectly weight-, BMIand fat mass-matched controls showed that women with PCOS have lower insulin sensitivity indices (defined as the ratio of the glucose disposal rate to the insulin concentration at the end of the clamp) (Dunaif et al., 1989 (Dunaif et al., , 1992 Diamanti-Kandarakis et al., 1995 therefore, did not exclude for differences in visceral and subcutaneous fat volumes between lean PCOS cases and controls. One of the fundamental questions in PCOS research is whether visceral fat volume changes more rapidly than subcutaneous fat volume during either ageing, use of hormone-containing formulations [such as clomiphene citrate and recombinant FSH (rFSH)], or weight change. Studies in weight-stable healthy women have shown no such preference for visceral fat accumulation through life. For example, effects on body fat distribution due to endocrine ageing (going through menopause) without concomitant weight change have been studied longitudinally with MRI imaging. Increasing subcutaneous and visceral fat content without preference for distribution was shown (Franklin et al., 2009 ). This coupling of subcutaneous and visceral fat content has also been shown, both in healthy premenopausal women without diabetes during cycles of weight change and during a hypo-caloric diet with or without extra exercise (van der Kooy et al., 1993; Janssen et al., 2002) . However, a different picture emerges for states of insulin resistance, for example type 2 diabetes or weight gain in anorexia nervosa. For example, in type 2 diabetes it has been shown that subcutaneous abdominal fat content will decrease with caloric restriction, while additional exercise is needed to decrease visceral fat content resulting in less insulin resistance (Giannopoulou et al., 2005) . MRI assessment of 22% weight gain during a mean period of 10.1 + 2.9 weeks (range: 4-17.3 weeks) in anorexia nervosa has shown temporary accumulation of mainly visceral fat (Mayer et al., 2009) . Moreover, weight recovery in anorectic women who managed to maintain body weight over a period of 1 year showed redistribution of adipose tissue deposition similarly to matched controls (Mayer et al., 2009) . To date, there are no longitudinal MRI studies on body fat distribution in lean women with PCOS to test the hypothesis that preferred visceral fat deposition is primarily driven by insulin resistance. Therefore, the hypothesis that preponderant visceral fat deposition is primarily driven by insulin resistance could also be vice versa, i.e. that insulin resistance is primarily driven by preferred visceral fat deposition. PCOS cases in the current study were younger than controls but disclosed hormonal differences, less visceral fat and larger ovarian volumes. Moreover, we found a 44.4 and 33.1% larger ovarian volume of the right and left side, recording dimensions along the x-, y-and z-axes. The x-axis was the maximal longitudinal axis calculated by the number of axial 6 mm steps along the spatial orientation of the ovary, the y-and z-axis being the largest anteroposterior and transverse diameters. Calculations were performed by using a mathematical ellipsoid formula (VE ¼ 2/3p . x . y . z). Notably, volume differences of 42% on average have been previously reported with calculations based on axial, sagittal and coronal diameters (calculated as 0.5× the diameters; Barber et al., 2010) . Unfortunately, the MRI technology that we have used turned out to be inappropriate for reliable calculations of ovarian morphology (follicle number, peripheral follicle location, visible central ovarian stroma), perhaps because of the 1.0 T scanner that was used and/or the absence of coronary images.
The study protocol was written in the supposition that visceral fat is preponderant in PCOS, even in lean cases. Indeed, a higher visceral fat content has been shown in PCOS women but only in mildly obese cases. However, there was no such difference after matching groups for BIA-determined total fat mass (Barber et al., 2008) . The number of included women in this study was intentionally based on reported differences in favour of visceral fat accumulation in PCOS according to calculations in the whole group. In addition, the focus of the current study was to match for fat mass as close as possible, meaning that small subjects numbers were acceptable according to power analysis. Yet, small patient numbers remain a limitation of the study leaving subtle differences of glucose/insulin metabolism undetected. However, the strength of the current study is that it used MRI to assess body fat distribution. MRI is an objective imaging with a relatively low reliance on operator skill and with high resolution images. Moreover, serial MRI measurements were used to compare lean PCOS cases with controls.
Both groups were strictly matched according to study protocol. However, there was a 5.5-years difference of age, which we believe is the consequence of how control cases were selected. Fertile women were allocated to the control group if they matched for anthropometrics, if there was no contraceptive use, if ovulatory menstrual cycles were confirmed and if they have had successful pregnancies. It remains unlikely that a small age difference among women in their late twenties and early thirties can influence current findings. This belief is supported by the demonstration of total weight gain accompanied by selective accumulation of visceral fat that commonly starts of shortly before menopause (Lovejoy et al., 2008) .
In conclusion, this study adds new information to recent findings, i.e. mildly obese women with PCOS have no preponderant accumulation of visceral fat. The presented data demonstrated that lean PCOS cases have less visceral fat when compared with control cases. Since this is a cross-sectional study, we encourage further longitudinal studies for analysing visceral fat accumulation over time.
